- Home
- LNN vs JANX Comparison
LNN vs JANX Comparison
Compare LNN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNN
- JANX
- Stock Information
- Founded
- LNN 1954
- JANX 2017
- Country
- LNN United States
- JANX United States
- Employees
- LNN N/A
- JANX N/A
- Industry
- LNN Industrial Machinery/Components
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- LNN Industrials
- JANX Health Care
- Exchange
- LNN Nasdaq
- JANX Nasdaq
- Market Cap
- LNN 1.5B
- JANX 1.4B
- IPO Year
- LNN 1988
- JANX 2021
- Fundamental
- Price
- LNN $139.79
- JANX $24.05
- Analyst Decision
- LNN Hold
- JANX Strong Buy
- Analyst Count
- LNN 1
- JANX 11
- Target Price
- LNN $136.00
- JANX $76.55
- AVG Volume (30 Days)
- LNN 114.2K
- JANX 790.8K
- Earning Date
- LNN 10-23-2025
- JANX 11-05-2025
- Dividend Yield
- LNN 1.03%
- JANX N/A
- EPS Growth
- LNN 5.71
- JANX N/A
- EPS
- LNN 6.96
- JANX N/A
- Revenue
- LNN $677,807,000.00
- JANX $439,000.00
- Revenue This Year
- LNN $13.09
- JANX N/A
- Revenue Next Year
- LNN N/A
- JANX $130.50
- P/E Ratio
- LNN $20.11
- JANX N/A
- Revenue Growth
- LNN 9.46
- JANX N/A
- 52 Week Low
- LNN $112.14
- JANX $21.73
- 52 Week High
- LNN $150.96
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- LNN 49.11
- JANX 46.31
- Support Level
- LNN $139.06
- JANX $22.23
- Resistance Level
- LNN $143.22
- JANX $24.57
- Average True Range (ATR)
- LNN 2.47
- JANX 1.20
- MACD
- LNN -0.01
- JANX -0.03
- Stochastic Oscillator
- LNN 42.32
- JANX 31.49
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.